MedPath

Prevention by HMGCoA reductase inhibition of ALI associated with one lung ventilation following oesophagectomy by a Reduction of Pulmonary vascular dysfunction and inflammation (Prevention-HARP) - Acute lung injury post one lung ventilation; effects of simvastati

Phase 1
Conditions
Acute lung injury (ALI)
Registration Number
EUCTR2007-002454-37-GB
Lead Sponsor
The Royal Group Hospitals Trust
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Not specified
Target Recruitment
40
Inclusion Criteria

Adult patients undergoing oesophagectomy for oesophageal cancer at the Royal Victoria Hospital, Belfast (RVH)
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

•age < 18 years
•creatinine kinase (CK) > 5 times upper limit normal range
•known active liver disease (Child’s Pugh score > 11), or abnormal liver function tests: transaminases > 3 times upper limit normal range
•renal impairment (calculated creatinine clearance less than 30mL/minute)
•inability to take oral medication pre-operatively
•known lactose intolerance
•participation in other intervention trials within 30 days
•pregnancy, breast-feeding or women of childbearing potential not using adequate contraception;
•patients taking corticosteroids or non-steroidal anti-inflammatory drugs
•current treatment with statins
•known hypersensitivity to the study medication
•a previous adverse reaction to statins
•concomitant use of fibrates or other lipid-lowering therapy
•concomitant use of itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, grapefruit juice, cyclosporine, danazol, amiodarone, verapamil or diltiazem.
•consent declined

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath